AVIR Q3 2020 Earnings — Atea Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AVIRAtea Pharmaceuticals, Inc.

$484M

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$14M

Operating Income

-$18M

Net Income

-$18M

EPS (Diluted)

$-0.22

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$110M

Total Liabilities

$11M

Stockholders' Equity

$99M

Cash & Equivalents

$105M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$14M	$0	—
Operating Income	-$18M	-$4M	-367.7%
Net Income	-$18M	-$4M	-385.2%